SCHEMBL5456884

SCHEMBL5456884

Nc1nc2ccc(Oc3ccc(Nc4nc5cc(C(F)(F)F)cc(Cl)c5[nH]4)cc3)cc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
TP53 P04637 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
KDR P35968 6/20 0.44
CYP3A4 P08684 4/20 0.43
SCN4A P35499 2/20 0.43
CYP1A2 P05177 2/20 0.43
HSD17B10 Q99714 2/20 0.43
SCN9A Q15858 2/20 0.43
GMNN O75496 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456978 0.79 KDR (0.35) SMN1; SMN2HTTKDRSCN9ASCN5A
SCHEMBL5450095 0.78 KDR (0.44) SMN1; SMN2MAPTHTTKDRLMNA
SCHEMBL14521447 0.77 POLB (0.41) TP53SMN1; SMN2MAPTHTTKDR
SCHEMBL18004108 0.75 SCN4A (0.70) NPC1RAB9ATP53SMN1; SMN2MAPT
SCHEMBL30451659 0.75 SCN4A (0.70) NPC1RAB9ATP53SMN1; SMN2MAPT
SCHEMBL5459695 0.73 KDR (0.41) KDRRAF1BRAFTEK
SCHEMBL10694424 0.73 SCN4A (0.63) NPC1RAB9ATP53SMN1; SMN2MAPT
SCHEMBL5448427 0.73 KDR (0.41) KDRSCN9ASCN5ARAF1BRAF
SCHEMBL5453152 0.71 KDM4E (0.46) NPC1RAB9ASMN1; SMN2MAPTHTT
SCHEMBL10695695 0.71 SCN4A (0.53) NPC1RAB9ATP53SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021456-A1 Aminobenzimidazole derivatives MERCK PATENT GMBH (DE) 2007-01-25 US claimed
EP-1656377-A1 AMINOBENZIMIDAZOLE DERIVATIVES MERCK PATENT GmbH (DE) 2006-05-17 EP claimed
WO-2005019216-A1 AMINOBENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2005-03-03 WO claimed
US-20070021456-A1 Aminobenzimidazole derivatives MERCK PATENT GMBH (DE) 2007-01-25 US disclosed
US-20070021456-A1 Aminobenzimidazole derivatives MERCK PATENT GMBH (DE) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021456-A1 Aminobenzimidazole derivatives TIE1, KDR, FLT1 NPC1 4850/4885RAB9A 2936/4885TP53 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.